FAQ

BMS-911543

Known as: JAK2 Inhibitor BMS-911543 
An orally available small molecule targeting a subset of Janus-associated kinase (JAK) with potential antineoplastic activity. JAK2 inhibitor BMS… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2014
01220122014

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Related mentions per year

Related mentions per year

2010-2017
201020122014201620182020
BMS-911543
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Single agent BMS-911543 Jak2 inhibitor has distinct inhibitory effects on STAT5 signaling in genetically engineered mice with pancreatic cancer.
The Jak/STAT pathway is activated in human pancreatic ductal adenocarcinoma (PDAC) and cooperates with mutant Kras to drive… (More)
Is this relevant?
2015
2015
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Activation of Janus kinase 2 (JAK2), frequently as a result of the JAK2(V617F) mutation, is a characteristic feature of the… (More)
Is this relevant?
2015
2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential… (More)
Is this relevant?
2015
2015
Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543.
BMS-911543 is a complex pyrrolopyridine investigated as a potential treatment for myeloproliferative disorders. The development… (More)
Is this relevant?
2015
2015
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
Herein we report a rapid, accurate and robust UHPLC-MS/MS assay for the quantitation of BMS-911453, a Janus kinase 2 inhibitor… (More)
  • figure 3
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?
2015
2015
Integration of Physiologically-Based Pharmacokinetic Modeling into Early Clinical Development: An Investigation of the Pharmacokinetic Nonlinearity
BMS-911543, a promising anticancer agent, exhibited time-dependent and dose-dependent nonlinear pharmacokinetics (PKs) in its… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
BMS-911543 inhibits viability of tumor and stromal cells and limits disease progression in genetically engineered mice with pancreatic cancer
Pancreatic cancer (PCa) is resistant to cytotoxic therapies, and the profound immune suppressive nature of this disease renders… (More)
Is this relevant?
2014
2014
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells
Imatinib Mesylate (IM) and other tyrosine kinase inhibitor (TKI) therapies have had a major impact on the treatment of chronic… (More)
Is this relevant?
2012
2012
Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2
We report the characterization of BMS-911543, a potent and selective small-molecule inhibitor of the Janus kinase (JAK) family… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2012
Review
2012
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
JAK-STAT (Janus associated kinase-signal transducer and activator of transcription) pathway plays a critical role in transduction… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?